H2A Admin Core
H2A 管理核心
基本信息
- 批准号:10471412
- 负责人:
- 金额:$ 22.14万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-09-09 至 2025-08-31
- 项目状态:未结题
- 来源:
- 关键词:AccountingAdvocateAfricaAfrica South of the SaharaAfricanAgeBiological Specimen BanksCell NucleusClinicalCollaborationsCommunicationCommunitiesComputer softwareCountryData CollectionDatabase Management SystemsDevelopmentDocumentationElectronic MailEnsureFaceGenerationsGoalsGrantHIVHepatitis BHepatitis B VirusHepatitis C virusHumanInfectionInterceptInternationalInterruptionLeadLeadershipLinkMalignant NeoplasmsMedicalMentorsMonitorOnline SystemsPatient RecruitmentsPatientsPeer ReviewPeriodicityPoliciesPreparationPrimary carcinoma of the liver cellsProblem SolvingProgress ReportsPublic RelationsPublicationsReportingResearchResearch PersonnelResourcesReview LiteratureRisk FactorsRoleSchistosoma mansonii infectionSenegalSiteStructureSupervisionTimeTrainingUgandaUniversitiesWorkchronic infectiondata harmonizationdata sharingexpectationhuman subject protectionmeetingsorganizational structureparticipant retentionprogramssymposiumweb site
项目摘要
Hepatocellular carcinoma (HCC) is a very common and lethal cancer in Africa, and as patients with HIV live
longer, the HCC burden may increase. In prior studies, our team identified chronic infection with hepatitis B
and C viruses (HBV, HCV), HIV and Schistosomiasis mansoni as independent risk factors for HCC. Compared
to the US, HCC in sub-Saharan Africa occurs at younger age and more advanced stage with survival of only
months. Proposed is an East and West African partnership between colleagues at Makerere University in
Uganda, Fann University in Senegal and Johns Hopkins University focused on HIV and hepatocellular
carcinoma (HCC) in Africa: The H2A Consortium. Building on long-standing collaborative research, mentoring
and clinical activities in both countries, our overarching goal is to reduce the heavy burden of HCC in sub-
Saharan Africa. We advocate investigating cancer interception strategies using appropriate medical treatments
to interrupt or reverse the impact of these HCC-causing infections. The Administrative and Coordinating
Core (ACC) will provide overall leadership for implementing the scientific agenda of the H2A consortium. Using
best practices from decades of international research collaboration, the H2A Consortium proposes an effective
organizational structure and strong leadership with a track record of international research collaboration. The
organizational framework builds upon the ongoing close working relationship between prior co-PIs from
Uganda and Hopkins and welcomes the Senegalese team as equal partners. The ACC will establish
transparent structures to support rigorous study oversight, effective communication, and efficient problem-
solving. The H2A Consortium effectively integrates ACC activities within a closely interacting Steering
Committee (SC) comprised of the Overall Co-Leaders and the Project /Core PIs. For each Project or Core, the
leadership represents an equitable partnership with PIs from each site sharing responsibilities. This leadership
nucleus is further supported by an External Advisory Panel (EAP) and a Community Advisory Panel (CAP),
with collaborative links to NCI Program leadership and other U54 Consortia sites. The impact of our integrated
research and capacity development activities will be establishment of the H2A Consortium as partnered
Centers of Excellence on HIV and HCC in East and West Africa.
肝细胞癌在非洲是一种非常常见和致命的癌症,作为艾滋病毒携带者的患者生活在非洲。
时间长了,肝细胞癌的负担可能会增加。在之前的研究中,我们的团队确认了慢性乙肝感染
C病毒(乙肝病毒、丙型肝炎病毒)、HIV和曼氏血吸虫病是肝细胞癌的独立危险因素。相比较
对美国来说,撒哈拉以南非洲的肝癌发生在较年轻和较晚期的患者中,仅
月份。Makerere大学的同事们提议在东非和西非建立伙伴关系
乌干达、塞内加尔范恩大学和约翰霍普金斯大学专注于艾滋病毒和肝细胞
非洲的癌症(肝癌):H_2A联盟。建立在长期合作研究、指导的基础上
和临床活动,我们的首要目标是减轻亚洲区的肝癌负担
撒哈拉非洲。我们主张使用适当的医疗手段研究癌症拦截策略。
以阻断或逆转这些引起肝癌的感染的影响。管理与协调
CORE(行政协调会)将为执行H_2A财团的科学议程提供全面领导。vbl.使用
来自数十年国际研究合作的最佳实践,H2 A联盟提出了一种有效的
组织结构和强大的领导力,具有国际研究合作的记录。这个
组织框架建立在以前的合作绩效指标之间持续密切的工作关系基础上
乌干达和霍普金斯大学,并欢迎塞内加尔团队作为平等伙伴。行政协调委员会将建立
透明的结构,支持严格的研究监督、有效的沟通和高效的问题-
解决问题。H_2A联盟有效地将行政协调委员会的活动整合到密切互动的指导中
由总体共同领导和项目/核心绩效指标组成的委员会(SC)。对于每个项目或核心,
领导力代表着与每个站点的PI建立公平的伙伴关系,共同承担责任。这个领导层
中心还得到了一个外部咨询小组和一个社区咨询小组的支持,
与NCI计划领导力和其他U54联盟站点的协作链接。我们一体化的影响
研究和能力发展活动将作为合作伙伴建立氢氧化氢财团
东非和西非艾滋病毒和肝癌英才中心。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Gregory D Kirk其他文献
Risk of anal cancer in HIV-infected patients and HIV-uninfected controls in North America
- DOI:
10.1186/1750-9378-5-s1-a70 - 发表时间:
2010-10-11 - 期刊:
- 影响因子:2.800
- 作者:
Michael J Silverberg;Bryan Lau;Yuezhou Jing;Gypsyamber D'Souza;Eric A Engels;John Gill;James J Goedert;Gregory D Kirk;Amy Justice;Robert Dubrow - 通讯作者:
Robert Dubrow
Association of Primary Care Engagement with Initiation and Continuation of Medication Treatment for Opioid Use Disorder Among Persons with a History of Injection Drug Use
初级保健参与与有注射吸毒史的人开始和继续阿片类药物使用障碍药物治疗的关系
- DOI:
- 发表时间:
2024 - 期刊:
- 影响因子:4.2
- 作者:
D. Sosnowski;K. Feder;Becky L. Genberg;S. Mehta;Gregory D Kirk - 通讯作者:
Gregory D Kirk
Association of immunosuppression and HIV viremia with anal cancer risk in persons living with HIV in the United States and Canada.
美国和加拿大艾滋病毒感染者的免疫抑制和艾滋病毒病毒血症与肛门癌风险的关联。
- DOI:
- 发表时间:
2019 - 期刊:
- 影响因子:11.8
- 作者:
R. Hernández;L. Qin;Haiqun Lin;W. Leyden;Romain S. Neugebauer;K. Althoff;N. Hessol;Chad J. Achenbach;J. T. Brooks;M. Gill;S. Grover;M. Horberg;Jun Li;W. C. Mathews;Á. Mayor;P. Patel;Charles S Rabkin;A. Rachlis;Amy C. Justice;Richard D. Moore;Eric A. Engels;M. Silverberg;R. Dubrow;Constance A. Benson;Ronald J. Bosch;Gregory D Kirk;Kenneth H. Mayer;C. Grasso;Robert S. Hogg;P. Richard Harrigan;J. Montaner;B. Yip;Julia Zhu;K. Salters;Karyn Gabler;K. Buchacz;Jun Li;K. Gebo;Richard D. Moore;B. Rodriguez;M. Horberg;M. Silverberg;Jennifer E. Thorne;Charles S Rabkin;Joseph B. Margolick;Lisa P. Jacobson;Gypsyamber D'Souza;M. Klein;A. Kroch;Ann N. Burchell;Adrian Betts;Joanne D. Lindsay;R. Hunter;Á. Mayor;M. John Gill;S. Deeks;Jeffrey N. Martin;J. T. Brooks;M. Saag;M. Mugavero;James Willig;W. C. Mathews;Joseph J Eron;S. Napravnik;M. Kitahata;Heidi M Crane;D. Drozd;Timothy R. Sterling;David Haas;Peter F. Rebeiro;M. Turner;Amy C. Justice;R. Dubrow;David A. Fiellin;S. Gange;K. Anastos;K. Althoff;R. Mckaig;Aimee M. Freeman;Stephen E. Van Rompaey;Liz Morton;J. McReynolds;William Lober;Jennifer S. Lee;Bin You;B. Hogan;Jinbing Zhang;Jerry Jing;E. Humes;Sally B Coburn - 通讯作者:
Sally B Coburn
Gregory D Kirk的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Gregory D Kirk', 18)}}的其他基金
Baltimore Oral Epidemiology, Disease Effects, and HIV Evaluation Study (BEEHIVE)
巴尔的摩口腔流行病学、疾病影响和 HIV 评估研究 (BEEHIVE)
- 批准号:
10668433 - 财政年份:2020
- 资助金额:
$ 22.14万 - 项目类别:
Research Supplements to Promote Diversity in Health-Related Research
促进健康相关研究多样性的研究补充
- 批准号:
10643214 - 财政年份:2020
- 资助金额:
$ 22.14万 - 项目类别:
Antiviral treatment as prevention for HBV- and HBV/HIV-associated hepatocellular carcinoma
抗病毒治疗预防 HBV 和 HBV/HIV 相关肝细胞癌
- 批准号:
10689163 - 财政年份:2020
- 资助金额:
$ 22.14万 - 项目类别:
Antiviral treatment as prevention for HBV- and HBV/HIV-associated hepatocellular carcinoma
抗病毒治疗预防 HBV 和 HBV/HIV 相关肝细胞癌
- 批准号:
10259886 - 财政年份:2020
- 资助金额:
$ 22.14万 - 项目类别:
Baltimore Oral Epidemiology, Disease Effects, and HIV Evaluation Study (BEEHIVE)
巴尔的摩口腔流行病学、疾病影响和 HIV 评估研究 (BEEHIVE)
- 批准号:
10223266 - 财政年份:2020
- 资助金额:
$ 22.14万 - 项目类别:
Study of HIV Infection in the Etiology of Lung Disease (SHIELD) AIR: Air Pollution Impact on Respiratory Health in HIV
HIV 感染与肺部疾病病因学研究 (SHIELD) 空气:空气污染对 HIV 呼吸系统健康的影响
- 批准号:
10664953 - 财政年份:2020
- 资助金额:
$ 22.14万 - 项目类别:
相似海外基金
Optimizing Health and Well-Being of Diverse Mothers with IDD and Their Infants During the Perinatal Period: A Virtual Advocate Tool for Data-Driven Supports
优化患有 IDD 的不同母亲及其婴儿在围产期的健康和福祉:用于数据驱动支持的虚拟倡导工具
- 批准号:
10760051 - 财政年份:2023
- 资助金额:
$ 22.14万 - 项目类别:
POSE: Phase II: Advocate Led Long-term Gameplan for Open OnDemand (ALL GOOD)
POSE:第二阶段:倡导者主导 Open OnDemand 的长期游戏计划(一切顺利)
- 批准号:
2303692 - 财政年份:2023
- 资助金额:
$ 22.14万 - 项目类别:
Standard Grant
Capitalising on our differences: A gathering to better understand and advocate for Early Career Health Researchers in Canada
利用我们的差异:更好地理解和倡导加拿大早期职业健康研究人员的聚会
- 批准号:
468168 - 财政年份:2022
- 资助金额:
$ 22.14万 - 项目类别:
Miscellaneous Programs
Addressing social adversity to improve outcomes among children undergoing liver transplant: the role for a health advocate on the transplant team
解决社会逆境以改善接受肝移植的儿童的预后:移植团队中健康倡导者的作用
- 批准号:
10427960 - 财政年份:2022
- 资助金额:
$ 22.14万 - 项目类别:
Evaluating an ACEs-Targeting Advocate Model of a Substance Use Prevention Program
评估药物使用预防计划的针对 ACE 的倡导者模型
- 批准号:
10577074 - 财政年份:2022
- 资助金额:
$ 22.14万 - 项目类别:
The Art of Creation: Using Art-Based Knowledge Translation to Promote and Advocate for a Healthy Start to Life
创造的艺术:利用基于艺术的知识转化来促进和倡导健康的生命开端
- 批准号:
486588 - 财政年份:2022
- 资助金额:
$ 22.14万 - 项目类别:
Studentship Programs
When I am Old, I shall Wear Purple Nail Varnish: Utilising performance art to construct queer spaces that celebrate and advocate for ageing bodies
当我老了,我要涂紫色指甲油:利用行为艺术构建酷儿空间,庆祝和倡导衰老的身体
- 批准号:
2760091 - 财政年份:2022
- 资助金额:
$ 22.14万 - 项目类别:
Studentship
Addressing social adversity to improve outcomes among children undergoing liver transplant: the role for a health advocate on the transplant team
解决社会逆境以改善接受肝移植的儿童的预后:移植团队中健康倡导者的作用
- 批准号:
10621188 - 财政年份:2022
- 资助金额:
$ 22.14万 - 项目类别:
Techquity by FAITH!: A cluster randomized controlled trial to assess the efficacy of a community-informed, cardiovascular health promotion mobile hlth intervention with digital health advocate support
Techquity by FAITH!:一项整群随机对照试验,旨在评估社区知情、心血管健康促进移动 hlth 干预措施在数字健康倡导者支持下的效果
- 批准号:
10891016 - 财政年份:2021
- 资助金额:
$ 22.14万 - 项目类别:
CMV responses in autoantibody positive subjects advocate antiviral treatments for prevention of T1D
自身抗体阳性受试者的 CMV 反应主张抗病毒治疗以预防 T1D
- 批准号:
10230365 - 财政年份:2020
- 资助金额:
$ 22.14万 - 项目类别:














{{item.name}}会员




